AAP
ARCT icon

Ardsley Advisory Partners’s Arcturus Therapeutics ARCT Stock Holding History

Ardsley Advisory Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,143
Closed -$56K – 189
2014
Q4 		$56K Buy
+2,143
New +$68.1K 0.01% 179

Other funds holding ARCT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Ardsley Advisory Partners's ARCT Position: Q1 2015 in Review

Ardsley Advisory Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2015, closing a stake of 2,143 shares — an estimated $56K sold.

Ardsley Advisory Partners first reported a position in ARCT in Q4 2014 and held it in 1 quarter. The position peaked at $56K in Q4 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q1 2015.

  • Ardsley Advisory Partners reported no remaining Arcturus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Ardsley Advisory Partners sold 2,143 Arcturus Therapeutics shares in Q1 2015, an estimated $56K.
  • Ardsley Advisory Partners first reported a position in Arcturus Therapeutics in Q4 2014 and held it in 1 quarter.
  • Ardsley Advisory Partners's Arcturus Therapeutics position peaked at $56K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2015.

Based on Ardsley Advisory Partners's 13F filing for Q1 2015, filed 15 May 2015.